Cancer Family
Esophageal Neoplasm
CI-CAN-00000174Explore in graph →
Non-malignant555 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000174Explore in graph →
Clinical trials
2,208 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03529266 | Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma.(PLACE020) | completed | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01077999 | Chemoradiation and Panitumumab for Esophageal Cancer | completed | Phase 2 | 78 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01217060 | Trimodality Management of T1b Esophageal Cancers | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02128243 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer(MATEO) | completed | Phase 2 | 242 | AIO-Studien-gGmbHOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01463605 | Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial | completed | Phase 2 | 46 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03116152 | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | completed | Phase 2 | 190 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04225364 | Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 56 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03274011 | Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02606916 | Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer. | completed | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT01928290 | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer(FOLFIRINOX) | completed | Phase 2 | 67 | Washington University School of MedicineOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03187314 | Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer | completed | Phase 2 | 25 | Hangzhou Cancer HospitalOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT00985192 | Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer | completed | Phase 2 | 49 | Translational Oncology Research InternationalOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00003748 | Irinotecan in Treating Patients With Esophageal or Stomach Cancer | completed | Phase 2 | 40 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00020761 | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach | completed | Phase 2 | 51 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT02120911 | Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma(TRAP) | completed | Phase 1 / Phase 2 | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT01913639 | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | completed | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT03087864 | PDL-1 Targeting in Resectable Oesophageal Cancer(PERFECT) | completed | Phase 2 | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT01787006 | Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer | completed | Phase 2 | 74 | University Hospital Schleswig-HolsteinOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01362127 | Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia(NeoRes) | completed | Phase 2 | 181 | Karolinska University HospitalOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT00439608 | Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer | completed | Phase 2 | 60 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00522795 | Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001) | completed | Phase 2 | 40 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01747551 | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | completed | Phase 2 | 64 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01348217 | Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus(CONCORDE) | completed | Phase 2 / Phase 3 | 196 | Centre Georges Francois LeclercOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01498289 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | completed | Phase 2 | 213 | SWOG Cancer Research NetworkNETWORK | 1 | Nov 7, 2019 | clinicaltrials |
| NCT02406170 | Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma(REPEAT) | completed | Phase 1 / Phase 2 | 47 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02843581 | Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01855854 | Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH | completed | Phase 2 | 54 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT02649361 | Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) | completed | Phase 2 | 164 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03584308 | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | completed | Phase 2 | 110 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT00601705 | Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach | completed | Phase 2 | 61 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT00917462 | Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00217581 | Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer | completed | Phase 2 | 39 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT01715233 | Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. | completed | Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT01831531 | Study of S-1 in Combination With Radiotherapy in Esophageal Cancer | completed | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03292757 | FLOTOR Pilot Study(FLOTOR) | completed | Phase 1 / Phase 2 | 21 | Oxford University Hospitals NHS TrustOTHER | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00215644 | Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer(MATRIX EG) | completed | Phase 2 | 72 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Nov 2, 2018 | clinicaltrials |
| NCT00137813 | Avastin and Taxotere for Esophagogastric Cancer | completed | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00531180 | 4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00096031 | S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | completed | Phase 2 | 63 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00607594 | Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Aug 23, 2018 | clinicaltrials |
| NCT00891878 | Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 12 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00711412 | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer | completed | Phase 2 | 44 | Northwestern UniversityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01746043 | A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT00316862 | Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery | completed | Phase 2 | 82 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 8, 2018 | clinicaltrials |
| NCT00938470 | Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 73 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT00183872 | Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 40 | University of Southern CaliforniaOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT01612546 | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 10 | City of Hope Medical CenterOTHER | 1 | Feb 1, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2021source: clinicaltrials